Company News

 

Tauriga Sciences Inc. to Form Wholly Owned Subsidiary Focused on the Development …  View


Tauriga Sciences, Inc. announced that it has secured additional capital..  View


2014 – 2015 Financials Reported – Company On Track To Regain Reporting Status. View

LATEST TAURIGA SCIENCES UPDATES

NEW YORK, NY–(Marketwired – Mar 7, 2017) – Tauriga Sciences, Inc. ( OTC PINK : TAUG ) (“Tauriga” or “the Company”), a company engaged in building businesses in the life sciences space, has today provided its shareholders with an update on the status of its ongoing federal lawsuit against its predecessor audit firm Cowan Gunteski & Co. PA (“Cowan Gunteski”). This case is titled “Tauriga Sciences, Inc. v. Cowan, Gunteski & Co., P.A. et al” and is being tried in Federal District Court of New Jersey (the “Court”); Case No. 15-CV-62334.

Read More

TAURIGA SCIENCES, INC. RECEIVES NOTIFICATION FROM DTCC THAT THE COMPANY HAS BEEN APPROVED FOR DWAC SERVICES

January 28, 2017NEW YORK, NY–(Marketwired – Jan 27, 2017) – Tauriga Sciences, Inc. ( OTC PINK : TAUG ) (“Tauriga” or the “Company”), a company engaged in building businesses in the life sciences space, today announced that it has received approval from The Depository Trust

Read More

Tauriga Sciences, Inc. RolLeaf Branded Product Now Complete; Cannabidiol “CBD” Infused Roll On Product for Muscle Tension Relief

NEW YORK, NY–(Marketwired – Jan 3, 2017) – Tauriga Sciences, Inc. ( OTC PINK : TAUG ) (“Tauriga” or the “Company”), a company engaged in building businesses in the life sciences space, today announced it has completed the formulation, graphics, and …

Read More

Fully committed to commercializing innovation to enhance personal wellness, improve our environment and create lasting shareholder value.

Balanced Innovation and Commercialization

Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company focused on generating profitable revenues in the natural wellness sector and on developing a proprietary synthetic biology platform technology through its wholly-owned Pilus Energy subsidiary.

The Company’s business model is to create an attractive and balanced portfolio of life sciences assets without typical clinical regulatory timelines.

Tauriga’s main focus for the last year has been getting audited financials and relisted on BB. Due to what we believe was gross malpractice by our auditors, TAUG was delisted from the BB. But we are always looking for exciting opportunities to increase shareholder value.
Tauriga Sciences, Inc. (OTC PINK: TAUG) (“Tauriga” or the “Company”), a diversified life sciences technology Company, today announced that it has completed an equity private placement for $105,500 USD to date comprised of accredited individual investors as well as one institutional investor.
Recently the Company added Frank Orlowski, Sr. Director at Pfizer (PFE); and Keith Berman  CEO of Digital Diagnostics Inc (DECN). The Company remains committed to finding the right opportunity to joint venture or merge with.